Asia Pacific Asthma Drugs Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Medication (Quick Relief Medications and Long-Term Control Medications), Route of Administration (Inhaled, Prefilled Syringe/Vials, and Others), and Distribution Channel (Online Pharmacies, Hospital Pharmacies, and Retail Pharmacies)
The Asia Pacific asthma drugs market is expected to reach US$ 5,806.55 million by 2028 from US$ 3,783.73 million in 2021; it is estimated to grow at a CAGR of 6.3% from 2021 to 2028.
The growth of the market is due to the rising prevalence of asthma and the opportunities with commercialization of biologics are propelling the asthma drugs market growth. However, the unmet medical needs are hampering market growth.
Many asthma patients observed that identifying and avoiding triggers, taking a daily inhaled or oral controller drug, and utilizing a quick-relief inhaler when symptoms arise are enough to keep their asthma under control. However, these drugs are insufficient to treat asthma for some people. Several novel drugs, namely "biologics," have recently been licensed for the treatment of moderate-to-severe asthma. Biologics are different from other medications as it targets a specific antibody, molecule, or cell involved in asthma. As a result, biologics are called precision or personalized therapy.
A biologic is a drug derived from the cells of a live organism, such as bacteria or mice, tailored to target specific molecules in humans. Antibodies, inflammatory chemicals, and cell receptors are the targets for asthma biologics. By targeting these molecules, biologics attempt to disrupt the processes that contribute to inflammation, which causes asthma symptoms.
Biologics are given to patients who continue to experience symptoms despite taking normal daily controller drugs. Symptoms of poorly controlled asthma include recurrent hospital admissions, emergency room visits, or the need for oral steroids for exacerbations; waking up at night with difficulty breathing; requiring a fast-acting reliever medication, such as albuterol, several times a day or week; and requiring a fast-acting reliever medication, such as albuterol, several times a day or week. Before prescribing a biologic, clinicians ensure that the patient is taking all of their other controller medications as prescribed, avoiding any potential triggers, and treating any other medical illnesses that can be exacerbating their asthma.
The main advantage of biologics has been a reduction in many asthma exacerbations, including ER visits, hospitalizations, and the need for oral steroids. Reduced asthma symptoms, lower dosages of other controller medications, and fewer missed school and workdays are other advantages of biologics. Biologics improve asthmatic patients' quality of life. A few biologics have been reported to help people with severe asthma improve their lung function.
Currently, five biologics for asthma are approved—omalizumab, mepolizumab, reslizumab, benralizumab, and dupilumab. Omalizumab is an antibody that targets IgE allergy antibodies. Mepolizumab, reslizumab, and benralizumab target eosinophils, a type of cell that plays a role in allergic inflammation. Dupilumab is a monoclonal antibody that targets a receptor for two molecules that cause allergic inflammation. A doctor will obtain screening tests, such as blood work or environmental allergen skin prick testing, to determine which biologic can be the best possible way to treat asthma. Omalizumab is approved for patients aged six years old or older. All biologics, except for reslizumab, are approved for individuals aged 12 years old. Adults aged 18 and over are allowed to use reslizumab.
Biologics have been proved in trials to be quite safe and have a few side effects. Further, biologics are more expensive than other controller drugs, but the price is likely to drop due to increased demand, the introduction of new biologics, and large-scale manufacturing.
Asia Pacific Asthma Drugs Market Revenue and Forecast to 2028 (US$ Mn)
Get more information on this report :
ASIA PACIFIC ASTHMA DRUGS MARKET SEGMENTATION
The Asia Pacific asthma drugs market, by medication, is segmented into quick relief medications and long-term control medications. Based on route of administration, the market is segmented into inhaled, prefilled syringe/vials, and others. Based on distribution channel, the Asia Pacific asthma drugs market is segmented into online pharmacies, hospital pharmacies, and retail pharmacies. By country, the market is segmented into the India, China, Japan, Australia, South Korea and Rest of Asia Pacific.
AstraZeneca; TEVA PHARMACEUTICAL INDUSTRIES LTD; Boehringer Ingelheim International GmbH, GlaxoSmithKline plc., Merck & Co., Inc., Koninklijke Philips N.V., Sanofi, Pfizer Inc. (Arena Pharmaceutical GmbH), Novartis AG and Abbott are among the leading companies operating in the Asia Pacific asthma drugs market.
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 Asia Pacific Asthma Drugs Market – By Medication
1.3.2 Asia Pacific Asthma Drugs Market – By Route of Administration
1.3.3 Asia Pacific Asthma Drugs Market – By Distribution Channel
1.3.4 Asia Pacific Asthma Drugs Market – By Country
2. Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Asia Pacific Asthma Drugs Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 Asia Pacific– PEST Analysis
4.3 Expert Opinion
5. Asthma Drugs Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Growing Environmental Implications & Genetic Implications of Air Pollution
5.1.2 More Vulnerability in Specific Ethnic Groups
5.1.3 Growing Exposure to Coarse Particulate Matters
5.1.4 Growing Prevalence of Physiological Disorders Harboring Asthma
5.2 Market Restraints
5.2.1 Unmet Medical Needs
5.3 Market Opportunities
5.3.1 Opportunities with Commercialization of Biologics
5.4 Future Trends
5.4.1 Increasing Research Activities and Product Innovations
5.5 Impact Analysis
6. Asthma Drugs Market–Asia Pacific Analysis
6.1 Asia Pacific Asthma Drugs Market Revenue Forecast and Analysis
7. Asthma Drugs Market Analysis – by Medication
7.1 Overview
7.2 Asthma Drugs Market Revenue Share, by Medication (2021 and 2028)
7.3 Quick Relief Medications
7.3.1 Overview
7.3.2 Quick Relief Medications: Asthma Drugs Market – Revenue and Forecast to 2028 (US$ Million)
7.4 Long-term Control Medications
7.4.1 Overview
7.4.2 Long-term Control Medications: Asthma Drugs Market – Revenue and Forecast to 2028 (US$ Million)
8. Asthma Drugs Market Analysis – By Route of Administration
8.1 Overview
8.2 Asthma Drugs Market Revenue Share, By Route of Administration (2021 and 2028)
8.3 Inhaled
8.3.1 Overview
8.3.2 Inhaled: Asthma Drugs Market– Revenue and Forecast to 2028 (USD Million)
8.4 Prefilled Syringe/Vials
8.4.1 Overview
8.4.2 Prefilled Syringe/Vials: Asthma Drugs Market– Revenue and Forecast to 2028 (USD Million)
8.5 Others (Oral, Nasal, Ophthalmic Etc.)
8.5.1 Overview
8.5.2 Others: Asthma Drugs Market– Revenue and Forecast to 2028 (USD Million)
9. Asthma Drugs Market Analysis – By Distribution Channel
9.1 Overview
9.2 Asthma Drugs Market Revenue Share, By Distribution Channel (2021 and 2028)
9.3 Online Pharmacies
9.3.1 Overview
9.3.2 Online Pharmacies: Asthma Drugs Market– Revenue and Forecast to 2028 (USD Million)
9.4 Hospital Pharmacies
9.4.1 Overview
9.4.2 Hospital Pharmacies: Asthma Drugs Market– Revenue and Forecast to 2028 (USD Million)
9.5 Retail Pharmacies and Drugstores
9.5.1 Overview
9.5.2 Retail Pharmacies and Drugstores: Asthma Drugs Market– Revenue and Forecast to 2028 (USD Million)
10. Asthma Drugs Market – Asia Pacific Analysis
10.1 Asia Pacific: Asthma Drugs Market
10.1.1 Overview
10.1.2 Asia Pacific: Asthma Drugs Market - Revenue and Forecast to 2028 (USD Million)
10.1.3 Asia Pacific: Asthma Drugs Market, by Medication - Revenue and Forecast to 2028 (USD Million)
10.1.4 Asia Pacific: Asthma Drugs Market, by Route of Administration - Revenue and Forecast to 2028 (USD Million)
10.1.5 Asia Pacific: Asthma Drugs Market, by Distribution Channel - Revenue and Forecast to 2028 (USD Million)
10.1.6 Asia Pacific Asthma Drugs Market Revenue and Forecasts to 2028, By Country (%)
10.1.6.1 India Asthma Drugs Market Revenue and Forecasts to 2028 (US$ Mn)
10.1.6.1.1 India Asthma Drugs Market Revenue and Forecasts to 2028 (US$ Mn)
10.1.6.1.2 India: Asthma Drugs Market, by Medication - Revenue and Forecast to 2028 (USD Million)
10.1.6.1.3 India: Asthma Drugs Market, by Route of Administration - Revenue and Forecast to 2028 (USD Million)
10.1.6.1.4 India: Asthma Drugs Market, by Distribution Channel - Revenue and Forecast to 2028 (USD Million)
10.1.6.2 China Asthma Drugs Market Revenue and Forecasts to 2028 (US$ Mn)
10.1.6.2.1 China Asthma Drugs Market Revenue and Forecasts to 2028 (US$ Mn)
10.1.6.2.2 China: Asthma Drugs Market, by Medication - Revenue and Forecast to 2028 (USD Million)
10.1.6.2.3 China: Asthma Drugs Market, by Route of Administration - Revenue and Forecast to 2028 (USD Million)
10.1.6.2.4 China: Asthma Drugs Market, by Distribution Channel - Revenue and Forecast to 2028 (USD Million)
10.1.6.3 Japan Asthma Drugs Market Revenue and Forecasts to 2028 (US$ Mn)
10.1.6.3.1 Japan Asthma Drugs Market Revenue and Forecasts to 2028 (US$ Mn)
10.1.6.3.2 Japan: Asthma Drugs Market, by Medication - Revenue and Forecast to 2028 (USD Million)
10.1.6.3.3 Japan: Asthma Drugs Market, by Route of Administration - Revenue and Forecast to 2028 (USD Million)
10.1.6.3.4 Japan: Asthma Drugs Market, by Distribution Channel - Revenue and Forecast to 2028 (USD Million)
10.1.6.4 South Korea: Asthma Drugs Market – Revenue and Forecast to 2028 (US$ Thousand)
10.1.6.4.1 South Korea: Asthma Drugs Market – Revenue and Forecast to 2028 (US$ Million)
10.1.6.4.2 South Korea: Asthma Drugs Market, by Medication – Revenue and Forecast to 2028 (US$ Thousand)
10.1.6.4.3 South Korea: Asthma Drugs Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Thousand)
10.1.6.4.4 South Korea: Asthma Drugs Market, by Distribution channel – Revenue and Forecast to 2028 (US$ Thousand)
10.1.6.5 Australia: Asthma Drugs Market – Revenue and Forecast to 2028 (US$ Thousand)
10.1.6.5.1 Australia: Asthma Drugs Market – Revenue and Forecast to 2028 (US$ Million)
10.1.6.5.2 Australia: Asthma Drugs Market, by Medication– Revenue and Forecast to 2028 (US$ Thousand)
10.1.6.5.3 Australia: Asthma Drugs Market, by Route of Administration– Revenue and Forecast to 2028 (US$ Thousand)
10.1.6.5.4 Australia: Asthma Drugs Market, by Distribution Channel– Revenue and Forecast to 2028 (US$ Thousand)
10.1.6.6 Rest of Asia Pacific Asthma Drugs Market Revenue and Forecasts to 2028 (US$ Mn)
10.1.6.6.1 Rest of Asia Pacific Asthma Drugs Market Revenue and Forecasts to 2028 (US$ Mn)
10.1.6.6.2 Rest of Asia Pacific: Asthma Drugs Market, by Medication - Revenue and Forecast to 2028 (USD Million)
10.1.6.6.3 Rest of Asia Pacific: Asthma Drugs Market, by Route of Administration - Revenue and Forecast to 2028 (USD Million)
10.1.6.6.4 Rest of Asia Pacific: Asthma Drugs Market, by Distribution Channel - Revenue and Forecast to 2028 (USD Million)
11. Asthma Drugs Market–Industry Landscape
11.1 Overview
11.2 Organic Developments
11.2.1 Overview
11.3 Inorganic Developments
11.3.1 Overview
12. Company Profiles
12.1 AstraZeneca
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 TEVA PHARMACEUTICAL INDUSTRIES LTD
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 GlaxoSmithKline plc.
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Boehringer Ingelheim International GmbH
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 Merck & Co., Inc.
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 Koninklijke Philips N.V.
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Sanofi
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 Pfizer Inc. (Arena Pharmaceutical GmbH)
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
12.9 Novartis AG
12.9.1 Key Facts
12.9.2 Business Description
12.9.3 Products and Services
12.9.4 Financial Overview
12.9.5 SWOT Analysis
12.9.6 Key Developments
12.10 Abbott
12.10.1 Key Facts
12.10.2 Business Description
12.10.3 Products and Services
12.10.4 Financial Overview
12.10.5 SWOT Analysis
12.10.6 Key Developments
13. Appendix
13.1 About The Insight Partners
13.2 Glossary of Terms
LIST OF TABLES
Table 1. Odds Ratio (OR) For Mental Disorders among Adults with Asthma Vs Without Asthma
Table 2. Asthma Death Rates for Select Countries, 2018
Table 3. Common SABAs
Table 4. Commonly inhaled corticosteroids
Table 5. Asia Pacific Asthma Drugs Market, by Medication – Revenue and Forecast to 2028 (USD Million)
Table 6. Asia Pacific Asthma Drugs Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
Table 7. Asia Pacific Asthma Drugs Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
Table 8. India Asthma Drugs Market, by Medication – Revenue and Forecast to 2028 (USD Million)
Table 9. India Asthma Drugs Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
Table 10. India Asthma Drugs Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
Table 11. China Asthma Drugs Market, by Medication – Revenue and Forecast to 2028 (USD Million)
Table 12. China Asthma Drugs Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
Table 13. China Asthma Drugs Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
Table 14. Japan Asthma Drugs Market, by Medication – Revenue and Forecast to 2028 (USD Million)
Table 15. Japan Asthma Drugs Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
Table 16. Japan Asthma Drugs Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
Table 17. South Korea Asthma Drugs Market, by Medication – Revenue and Forecast to 2028 (US$ Thousand)
Table 18. South Korea Asthma Drugs Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Thousand)
Table 19. South Korea Asthma Drugs Market, by Distribution channel – Revenue and Forecast to 2028 (US$ Thousand)
Table 20. Australia Asthma Drugs Market, by Medication – Revenue and Forecast to 2028 (US$ Thousand)
Table 21. Australia Asthma Drugs Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Thousand)
Table 22. Australia Asthma Drugs Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Thousand)
Table 23. Rest of Asia Pacific Asthma Drugs Market, by Medication – Revenue and Forecast to 2028 (USD Million)
Table 24. Rest of Asia Pacific Asthma Drugs Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
Table 25. Rest of Asia Pacific Asthma Drugs Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
Table 26. Organic Developments in the Asthma Drugs Market
Table 27. Inorganic Developments in the Asthma Drugs Market
Table 28. Glossary of Terms, Asthma Drugs Market
LIST OF FIGURES
Figure 1. Asthma Drugs Market Segmentation
Figure 2. Asthma Drugs Market, By Country
Figure 3. Asia Pacific Asthma Drugs Market Overview
Figure 4. The Long Term Control Medications Segment Held Largest Share of Mode of Service in the Asthma Drugs Market
Figure 6. Asia Pacific Asthma Drugs Market- Leading Country Markets (US$ Million)
Figure 7. Asia Pacific PEST Analysis
Figure 8. Expert Opinion
Figure 9. Impact of Low Mood/Anxiety on Asthma
Figure 10. Asthma Drugs Market Impact Analysis of Drivers and Restraints
Figure 11. Asia Pacific Asthma Drugs Market– Revenue Forecast and Analysis – 2020- 2028
Figure 12. Asthma Drugs Market Revenue Share, by Medication (2021 and 2028)
Figure 13. Quick Relief Medications: Asthma Drugs Market – Revenue and Forecast to 2028 (US$ Million)
Figure 14. Long-term Control Medications: Asthma Drugs Market – Revenue and Forecast to 2028 (US$ Million)
Figure 15. Asthma Drugs Market Share, By Route of Administration, 2021 and 2028 (%)
Figure 16. Inhaled: Asthma Drugs Market– Revenue and Forecast to 2028 (USD Million)
Figure 17. Prefilled Syringe/Vials: Asthma Drugs Market– Revenue and Forecast to 2028 (USD Million)
Figure 18. Others: Asthma Drugs Market– Revenue and Forecast to 2028 (USD Million)
Figure 19. Asthma Drugs Market Share, By Distribution Channel, 2021 and 2028 (%)
Figure 20. Online Pharmacies: Asthma Drugs Market– Revenue and Forecast to 2028 (USD Million)
Figure 21. Hospital Pharmacies: Asthma Drugs Market– Revenue and Forecast to 2028 (USD Million)
Figure 22. Retail Pharmacies and Drugstores: Asthma Drugs Market– Revenue and Forecast to 2028 (USD Million)
Figure 23. Asia Pacific: Asthma Drugs Market, by Key Country – Revenue (2021) (USD Million)
Figure 24. Asia Pacific Asthma Drugs Market Revenue and Forecast to 2028 (USD Million)
Figure 25. Asia Pacific Asthma Drugs Market Revenue and Forecasts to 2028, By Country (%)
Figure 26. India Asthma Drugs Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 27. China Asthma Drugs Products Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 28. Japan Asthma Drugs Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 29. South Korea: Asthma Drugs Market – Revenue and Forecast to 2028 (US$ Thousand)
Figure 30. Australia: Asthma Drugs Market – Revenue and Forecast to 2028 (US$ Thousand)
Figure 31. Rest of Asia Pacific Asthma Drugs Market Revenue and Forecasts to 2028 (US$ Mn)
- AstraZeneca
- TEVA PHARMACEUTICAL INDUSTRIES LTD
- GlaxoSmithKline plc.
- Boehringer Ingelheim International GmbH
- GlaxoSmithKline plc.
- Merck & Co., Inc.
- Koninklijke Philips N.V.
- Sanofi
- Pfizer Inc. (Arena Pharmaceutical GmbH)
- Novartis AG
- Abbott
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Asia Pacific asthma drugs market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the Asia Pacific asthma drugs market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.